Healthcare

Organoids for drug development: 3 strategic considerations for your preclinical pipeline

Published on 12 June 2026 Read 25 min

organoids drug development agency consulting consultancy experts

Roughly 95% of drug candidates tested in animal studies go on to fail in clinical trials¹, a gap that costs the pharma industry billions annually and delays treatments reaching patients. Organoids, 3D organ models grown from stem cells or organ-specific cell types, are emerging as one of the most promising tools to close that gap, as more biologically relevant in vitro models. These structures range from simple single-organ models to more advanced systems like organ-on-chip technologies, integrating microfluidics to simulate physiological processes and multi-organ interactions.

Organoids are already playing an important role in:

R&D research, particularly in de-risking drug development by predicting toxicity and efficacy of early-stage drug candidates. Studies have shown improved organoid predictive value for drug-induced liver injury compared to animal models, with some achieving nearly 90% accuracy in appropriately identifying safe vs. unsafe compounds, as demonstrated in 2021².
Personalized treatment options, particularly in the oncology space for modeling an individual patient’s tumor, or for creating reproducible models of cancer subtypes for future drug discovery. Current preclinical models are both ethically and financially inefficient, underscoring the promise of organoids. By improving prediction of toxicity and efficacy in humans, organoids can help prioritize a smaller set of promising candidates and reduce costly downstream studies on ineffective or harmful compounds.

This article explores the regulatory landscape, current state of the art, and opportunities for improvement of R&D research using organoids.

Regulatory momentum: from permission to expectation

U.S. and Chinese innovation leadership

Organoids today are typically used to supplement, rather than replace, animal models. However, regulatory bodies increasingly recognize them as viable alternatives in certain contexts, including as preclinical evidence. In the United States, the Food & Drug Administration (FDA) 2022 Modernization Act 2.0 expanded the use case for organoids and other New Approach Methodologies (NAMs), removing the strict requirement for animal testing in preclinical studies. In April 2025, the FDA announced plans to phase out animal testing requirements for monoclonal antibodies, with immediate implementation. Three months later, the National Institutes of Health (NIH) supported this shift by launching the Organoid Research and Informatics Validation Alliance, awarding $87 million to standardization and benchmarking against animal models. In March 2026, the FDA released draft guidance establishing formal validation principles for NAMs, which is the clearest signal yet that regulatory mindsets are shifting from permission to expectation.

Alongside the major U.S. push towards the use of organoids, China has also taken a strong positive stance by becoming a leader in organoid-specific governance. China’s National Science and Technology Ethics Committee issued the Human Organoid Research Ethical Guidelines in April 2025, a comprehensive document outlining important clinical and ethical considerations for the use of organoids in research. Strong guidelines combined with a cultural push towards the use of novel organoid platforms that recapitulate human biology position China alongside the U.S. as a global leader in the adoption of organoids for R&D.

Globally, the European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) are formalizing early regulatory frameworks for organoids, albeit at a slower pace.

Progress on standardization & testing is key for regulatory adoption

Major health agencies emphasize the need for further testing and standardization before full replacement of animal models. Head-to-head validation studies, directly comparing the predictive accuracy of organoid vs. animal models, will be critical. These shifts reflect a longstanding public pressure to reduce animal testing, and recent policy changes highlight real momentum: NIH’s Complement Animal Research in Experimentation program aims to accelerate the development, standardization, validation, and use of alternative technologies including organoids, with $150 million committed.

Current and emerging applications of organoids across therapeutics areas

Current use cases of organoids in drug development

Oncology has been a pioneering field in organoid use. Tumor organoids that closely match patient genetics can be tested across multiple drugs to identify the most effective therapies. These can be made in bulk to effectively model a disease long-term, or produced to model a specific patient’s tumor for personalized medicine. In 2023, a team at Fred Hutchinson Cancer Center in Seattle collaborated with SEngine Precision Medicine to identify therapeutic options for a patient with stage IV ovarian carcinoma¹. This ex vivo testing led to a selection of treatment offering the patient 7 months of stable disease with manageable side effects, a major success given the poor prognosis for the patient and a highlight of the power of organoid technologies for personalized medicine. As more tumor models are developed for personalized medicine and broader oncology studies, the field will continue to expand.

Learn more about how our team can support you in your projects related to personalized medicine >

Gastrointestinal and Liver Diseases are another major area of organoid use. Modeling acute or genetic liver disease allows assessment of treatment options in a physiologically relevant context. Liver organoids can be used to assess toxicity early, helping filter out harmful candidates in R&D. Roche, in partnership with Cincinnati Children’s Hospital, successfully modeled immune-driven liver injury in an organoid model, paving the way for further predictive use of this technology².

Respiratory Disease research using organoids played a major role during the COVID-19 pandemic. Lung organoids helped assess efficacy and understand mechanism of action of viral treatments aimed at improving outcomes for patients with respiratory infections. RemdesivirTM, an anti-viral treatment for COVID-19, was tested for efficacy in human lung organoids³.

Emerging use cases of organoids in drug development

The human organoids market reached an estimated ~$1.2 billion in 2025, growing at roughly 20% CAGR, 2-3 times faster than the animal testing market (~6–8% CAGR)⁴⁵. The continued growth in the animal testing market is in line with growth in R&D testing (~6.5% CAGR)⁶. While the animal testing market remains larger today (estimated $10 billion vs. $1 billion) the trajectory points to organoids capturing a growing share of preclinical testing over the next decade.

Dermatology applications are an emerging field for organoids. Artificial skin is already standard for cosmetic safety testing as an ethical replacement for animal testing. L’Oreal has been a pioneer in this work, partnering with UC Berkeley and other industry and academic groups. Cosmetic work offers a strong foundation to build on for the dermatology field. Companies such as BioHive in France offer skin organoids for Pharma R&D research as well as cosmetics. These organoids contain the diverse cell types found in skin, and can even model inflammatory diseases and diverse skin types, helping propel dermatology research into new frontiers.

Cardiology is another emerging application field. A team of researchers in Australia used cardiac organoids to show that BET inhibition reduced the damaging effects of cardiac inflammation during SARS-CoV-2 infection⁷. Technical complexity of modeling the heart’s extracellular environment and its diverse tissue types remain a limiting factor to overcome before wider adoption of cardiac organoids.

Neurology presents both significant opportunity and complexity due to the brain’s cellular diversity. Recent advances have enabled human brain organoids to recapitulate key features of neurodegenerative diseases, including amyloid and tau pathology in Alzheimer’s disease. Because these neurodegenerative diseases have been notoriously difficult to model, further advances could unlock new therapeutic developments.

3 key considerations for overcoming technical limitations and building the right partnerships

For R&D leaders, understanding how and when to access the value of organoid technologies that are not yet fully mature is critical. Three technical frontiers shape this decision, and each points to a different strategic posture depending on the therapeutic area.

Key consideration 1: addressing the limited standardization of organoid growth and characteristics

Standardization typically lags behind early innovation, though protocols are improving, including guidelines from the American Type Culture Collection (ATCC). The ability to easily and robustly generate consistent organoids is a key consideration when deciding whether to build in-house or partner externally. For therapeutic areas where organoid models are well-established (GI, liver, oncology), internal programs or external partnerships can most likely deliver reproducible results today. For earlier-stage applications, partnering with specialized academic or biotech/CRO groups is likely the faster path. Future opportunities in standardization will come from automated workflows to even further reduce heterogeneity in organoid phenotypes and improve reproducibility of results.

Key consideration 2: improving vascularization to extend organoid size and longevity

Most current models lack vascularization and blood flow, often limiting the size and lifespan of organoids in culture. However, this frontier is moving fast: in June 2025, researchers at Stanford Medicine published a landmark study demonstrating the first heart and liver organoids with self-organizing blood vessel networks⁸. Their vascularized heart organoids contained 15–17 cell types, approaching the complexity of an early embryonic human heart. This breakthrough addresses one of biggest limitations in the field and opens the door to longer-lived, more physiologically relevant models for drug testing. For R&D teams in cardiology or hepatology, this is a space worth considering through partnerships or licensing rather than internal development.

Key consideration 3: enhancing immune cell integration

The lack of biologically relevant immune cells in culture limits organoid use, particularly for immunology. Researchers at Roche developed organoids incorporating tissue-resident immune cells, representing a major step forward⁹. Further advancements in immune cell incorporation have the power to improve organoids across fields, as immune cells play a critical role across diseases and organs. For most organizations, fully immune-competent organoid models remain an aspirational goal, a space to track through industry consortia and collaborative research rather than build in-house today.

The bottom line: organoid maturity varies dramatically by organ type and application. R&D teams that map their pipeline against this landscape and choose the right mix of internal investment, CRO & Biotech partnerships, and academic collaborations, will extract value faster.

With the FDA formalizing NAM validation standards and organoid adoption accelerating across therapeutic areas, the question is no longer whether organoids will reshape R&D pipelines, but how quickly your organization will integrate them.

Two questions to ask yourself when considering their utility for your R&D workflows:

What is the maturity level of organoids for my current pipeline? Which programs can leverage mature organoid models today, and which require a partnership strategy to access emerging capabilities?
What is the cost of waiting? As competitors adopt organoids to de-risk earlier and regulators increasingly expect NAM data, how does inaction affect our timeline and competitive position?

At Alcimed, we help pharma and biotech teams answer exactly that: assessing organoid readiness by therapeutic area, identifying relevant partners across the value chain, navigating evolving regulatory expectations, and many more. Do not hesitate to contact our team!

About the author,

Charles, Consultant in Alcimed’s Life Sciences team in the USA

Have a project and want to discuss it?

To go further

Cross-sector

3 TechBio business models to watch

Cure51: a platform for unlocking the value of biomedical data Founded in 2022, Cure51 is a TechBio company aiming to build a database from the clinical and molecular profiles of “exceptional ...
Healthcare

3 major approaches to implement in R&D to end pharmaceutical animal testing

Approach n°1: Using innovative technologies for in-vitro assays In the present advancing era of technologies, alternative methods for animal studies are being developed through innovative ...
Healthcare

How medical 3D printing can revolutionize research and development in pharmaceutical and biotech industries

3 areas in which medical 3D printing is a catalyst for innovation Area n°1: accelerating prototyping and design The ability of 3D printing to rapidly produce prototypes is changing the landscape ...